Get startedLog in
    Picture of Innovent Biologics logo

    1801 — Innovent Biologics News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapHigh Flyer
    All News

    Brief: Innovent Announces Strategic Collaboration With Lilly To Develop New Medicines Globally In Oncology And Immunology

    Picture of Innovent Biologics logoInnovent Biologics
    08/02/2026 10:09
    Feb 8 (Reuters) - Innovent Biologics Inc 1801.HK:

INNOVENT ANNOUNCES STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY

INNOVENT BIOLOGICS - INNOVENT WILL RECEIVE A $350 MILLION UPFRONT PAYMENT

INNOVENT BIOLOGICS: IS ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY & COMMERCIAL MILESTONE PAYMENTS UP TO EST $8.5 BILLION CONTINGEN CERTAIN FUTURE EVENTS

: INNOVENT ANNOUNCES STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY

Source text: ID:nPn5mzt1ta

Further company coverage: [1801.HK LLY.N]

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Innovent Biologics

    See all news